Vialwirebiotech, curated
November 21, 2026, 9:18 AM
October 8, 2026
- 10:02 AM · STAT News
- 9:42 AM · Pharmaceutical Executive9:42 AM<![CDATA[Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million ]]> — Pharmaceutical Executive
- 9:00 AM · BioWorld9:00 AMVtv’s HPPD designated US orphan drug for sickle cell disease — BioWorld
- 9:00 AM · BioWorld9:00 AMRibo announces EU CTA filing for RBD-3133 for obesity — BioWorld
- 9:00 AM · BioWorld9:00 AMTranscripta Bio and Synfini identify Huntington’s lead candidate — BioWorld
- 9:00 AM · PharmaVoice9:00 AMPharma’s $500B patent problem will come in waves — not as a cliff — PharmaVoice
- 9:00 AM · BioWorld9:00 AMDignify Therapeutics’ DTI-117 gains IND clearance — BioWorld
- 8:45 AM · Science (News)8:45 AMNIH revives network to study emerging diseases—but its new restrictions baffle scientists — Science (News)
- 8:00 AM · STAT News
- 6:00 AM · Drug Discovery World6:00 AMCancer Research UK and ORIC partner on CIP2A-targeted therapy — Drug Discovery World
- 4:30 AM · STAT News4:30 AMSTAT+: Biotech companies are struggling to navigate Trump’s new tariffs — STAT News
- 3:50 AM · Pharmaceutical Technology3:50 AM10x Genomics and Fred Hutch partner on cancer technologies — Pharmaceutical Technology
- 12:00 AM · Bloomberg — Technology12:00 AMAlphabet’s Isomorphic Labs in Funding Talks for at Least $40 Billion Value — Bloomberg — Technology
October 7, 2026
- 1:43 PM · Pharmaceutical Executive
- 12:00 PM · BioWorld12:00 PMTrade groups on the line as Rx companies seek SCOTUS review — BioWorld
- 12:00 PM · BioWorld12:00 PMAtsena’s gene therapy looks good in rare eye disease XLRS — BioWorld
- 12:00 PM · BioWorld12:00 PMKymathera grabs $80M series B for next-gen PI3Kα inhibitor — BioWorld
- 11:21 AM · BioPharma Dive11:21 AMHalozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial — BioPharma Dive
- 10:06 AM · STAT News10:06 AMSTAT+: Merck suffers a setback in Europe over its new Keytruda formulation — STAT News
- 9:43 AM · Pharmaceutical Technology9:43 AMCPHI 2026: Moderna builds on its COVID-era manufacturing lessons — Pharmaceutical Technology
- 9:42 AM · STAT News9:42 AMSTAT+: Forbion raises $2.6 billion, its largest fundraise to date — STAT News
- 9:38 AM · STAT News
- 9:00 AM · BioWorld9:00 AMAscletis’ amylin-incretin duo drives superior weight loss — BioWorld
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMCOR-1389 combines fat loss with muscle gain — BioWorld
- 9:00 AM · BioWorld9:00 AMNew financing at Matchpoint Therapeutics to advance lead program — BioWorld
- 9:00 AM · BioWorld9:00 AMCristae Therapeutics synthesizes new ROS production inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMPivot Therapeutics discovers new PI3K inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMPreclinical characterization of tegacorat for DMD — BioWorld
- 9:00 AM · BioWorld9:00 AMBMS patents RIPK1 inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMSTAT6-targeting compounds described in Hengrui patents — BioWorld
- 7:00 AM · Drug Discovery World7:00 AMFirst human trials in ovarian cancer for ‘armoured’ CAR-T therapy — Drug Discovery World
- 5:42 AM · Pharmaceutical Technology5:42 AMRocket receives $150m credit facility to advance cardiovascular portfolio — Pharmaceutical Technology
- 4:30 AM · STAT News
October 6, 2026
- 3:30 PM · Pharmaceutical Executive3:30 PM<![CDATA[MFN Raises the Stakes for Japan Launch Pricing]]> — Pharmaceutical Executive
- 12:40 PM · MIT Technology Review12:40 PMWeight-loss drugs show signs of slowing biological aging, say drugmakers — MIT Technology Review
- 12:12 PM · BioPharma Dive12:12 PMArriVent collapses on disappointing lung cancer data — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMBD to invest $19B in the US to bring relief from future tariffs — BioWorld
- 12:00 PM · BioWorld12:00 PMRougetx’s $58M to target pericyte dysfunction in vascular disease — BioWorld
- 12:00 PM · BioWorld12:00 PMRoche drops Chugai, Hanmi assets amid ‘pipeline quality’ push — BioWorld
- 12:00 PM · BioWorld12:00 PMFirst Circuit considers stay keeping ACIP from meeting as is — BioWorld
- 12:00 PM · BioWorld12:00 PMTakeda’s zasocitinib raises bar for oral psoriasis drugs — BioWorld
- 12:00 PM · BioWorld12:00 PMQbiotics builds on 78% response with AU$40M raise — BioWorld
- 12:00 PM · BioWorld12:00 PMCSL expands nephrology ambitions with $1.6B-plus Alentis deal — BioWorld
- 12:00 PM · BioWorld12:00 PMShionogi doubles down on rare diseases with $2B Intrabio buy — BioWorld
- 12:00 PM · BioWorld12:00 PMFrom ‘holy grail’ hope to insolvency: Paradigm's rapid fall — BioWorld
- 11:42 AM · BioPharma Dive11:42 AMDual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial — BioPharma Dive
- 11:00 AM · Wired — Science11:00 AMA New Neurotech Startup Launches to Rival Sam Altman’s Merge Labs — Wired — Science
- 10:41 AM · STAT News10:41 AMSTAT+: AstraZeneca opens new Boston site — STAT News